Yu Guoyu, Lin Yuan, Dai Hanhao, Xu Jie, Liu Jun
Clinical College of Orthopedics, Tianjin Medical University, Tianjin, China.
Department of Orthopedics, Fujian Provincial Hospital, Shengli Clinical Medical College, Fujian Medical University, Fuzhou, China.
Front Nutr. 2023 Feb 28;10:1016809. doi: 10.3389/fnut.2023.1016809. eCollection 2023.
Previous studies have not provided a consensus on the effect of serum 25-hydroxyvitamin D [25(OH)D] on osteoarthritis (OA). We aimed to evaluate the association using a large, nationally representative sample.
The cross-sectional data were obtained from the 2001 to 2018 National Health and Nutrition Examination Survey (NHANES). Individuals aged ≥40 years who had information of serum 25(OH)D, self-report OA, and related covariates were included. Multivariable logistic regression analysis was employed to assess the association between serum 25(OH)D and osteoarthritis.
Among the 21,334 participants included (weighted mean age, 56.9 years; 48.5% men), the proportion of participants with high serum 25(OH)D concentrations (≥100 nmol/L) increased significantly from 4.2% in 2001-2006 to 18.8% in 2013-2018. Higher serum 25(OH)D levels were associated with more osteoarthritis prevalence in fully adjusted model (odd ratio [OR] 1.25 [95% CI: 1.10, 1.43] for the 50-75 nmol/L group; OR 1.62 [95% CI: 1.42, 1.85] for the 75-100 nmol/L group; OR 1.91 [95% CI: 1.59, 2.30] for the ≥100 nmol/L group; with <50 nmol/L group as the reference) ( < 0.001 for trend). The association was consistent across several sensitivity analyses, including propensity score methods and excluding participants who had received vitamin D supplement. In subgroup analysis, the OR for the association increased significantly with body mass index (BMI) (BMI < 25 kg/m, 1.01 [95% CI: 1.04, 1.08]; BMI 25-30 kg/m, 1.05 [95% CI: 1.01, 1.08]; BMI ≥ 30 kg/m, 1.10 [95% CI: 1.06, 1.13]; = 0.004 for interaction).
There was a positive correlation between serum 25(OH)D and osteoarthritis with a possible modification by BMI. Our finding raises concerns about the potential adverse effects of high serum 25(OH)D on osteoarthritis, particularly among obese individuals. More well-designed studies are still needed to validate our findings in future.
既往研究对于血清25-羟基维生素D[25(OH)D]对骨关节炎(OA)的影响尚未达成共识。我们旨在使用一个具有全国代表性的大样本评估两者之间的关联。
横断面数据取自2001年至2018年的全国健康与营养检查调查(NHANES)。纳入年龄≥40岁且有血清25(OH)D信息、自我报告的OA及相关协变量的个体。采用多变量逻辑回归分析评估血清25(OH)D与骨关节炎之间的关联。
在纳入的21334名参与者中(加权平均年龄56.9岁;48.5%为男性),血清25(OH)D浓度高(≥100 nmol/L)的参与者比例从2001 - 2006年的4.2%显著增加至2013 - 2018年的18.8%。在完全调整模型中,较高的血清25(OH)D水平与更高的骨关节炎患病率相关(50 - 75 nmol/L组的比值比[OR]为1.25[95%CI:1.10,1.43];75 - 100 nmol/L组的OR为1.62[95%CI:1.42,1.85];≥100 nmol/L组的OR为1.91[95%CI:1.59,2.30];以<50 nmol/L组为参照)(趋势P<0.001)。在包括倾向评分法和排除接受维生素D补充剂的参与者在内的多项敏感性分析中,该关联一致。在亚组分析中,该关联的OR随体重指数(BMI)显著增加(BMI<25 kg/m²,1.01[95%CI:1.04,1.08];BMI 25 - 30 kg/m²,1.05[95%CI:1.01,1.08];BMI≥30 kg/m²,1.10[95%CI:1.06,1.13];交互作用P = 0.004)。
血清25(OH)D与骨关节炎之间存在正相关,且可能受BMI影响。我们的发现引发了对于高血清25(OH)D对骨关节炎潜在不良影响的担忧,尤其是在肥胖个体中。未来仍需要更多设计良好的研究来验证我们的发现。